Story
New drug 'functionally cures' many hepatitis B virus infections
1 report
1 website
1 discussion
Latest report
Overview
An experimental drug combined with standard antivirals has achieved a "functional cure" for 19% of participants in two trials involving chronic hepatitis B virus (HBV) infections. These results indicate that individuals can control the virus naturally without further treatment after a 6-month regimen.
Summary from science.org.
Reports
One report so far. Additional coverage will appear here when it is linked to this story.
Community reactions
Each reaction summarizes sampled comments from the linked discussion.
Hacker News · science.org
Hacker News discussion ↗
Historical count: 5 · 5 saved in sample · Historical sample
Analysis ready
Read this discussion’s reaction
Based on 5 sampled comments from this thread. Analyzed 2026-06-08.
- Praise: The trial's 19% success rate in functionally curing hepatitis B shows promise, especially as it has been independently replicated in over 1,800 patients, indicating potential for broader impact.
- Praise: The ability of Indian pharmaceutical companies to produce a biosimilar quickly could significantly reduce costs and improve access to treatment in underserved regions like Africa and Asia.
- Concern: The selection of non-cirrhotic patients in the trial raises concerns about the generalizability of the results, as most HBV-related deaths occur in patients with advanced disease.
- Concern: Despite the vaccine's existence, access issues mean that many people still suffer from hepatitis B, highlighting systemic healthcare challenges that need to be addressed.